80 related articles for article (PubMed ID: 16172791)
21. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
22. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract][Full Text] [Related]
23. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D
Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760
[TBL] [Abstract][Full Text] [Related]
24. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P
Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
[TBL] [Abstract][Full Text] [Related]
25. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
26. Celecoxib potentiates the anticancer effect of cisplatin on vulvar cancer cells independently of cyclooxygenase.
Kim SH; Kim SH; Song YC; Song YS
Ann N Y Acad Sci; 2009 Aug; 1171():635-41. PubMed ID: 19723114
[TBL] [Abstract][Full Text] [Related]
27. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours.
Kucab JE; Lee C; Chen CS; Zhu J; Gilks CB; Cheang M; Huntsman D; Yorida E; Emerman J; Pollak M; Dunn SE
Breast Cancer Res; 2005; 7(5):R796-807. PubMed ID: 16168126
[TBL] [Abstract][Full Text] [Related]
28. GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells.
Kim SH; Hwang CI; Juhnn YS; Lee JH; Park WY; Song YS
Carcinogenesis; 2007 Jan; 28(1):223-31. PubMed ID: 17166886
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
Cui W; Yu CH; Hu KQ
Clin Cancer Res; 2005 Nov; 11(22):8213-21. PubMed ID: 16299255
[TBL] [Abstract][Full Text] [Related]
30. [Correlation of p38 mitogen-activated protein kinase signal transduction pathway to uPA expression in breast cancer].
Han YC; Zeng XX; Wang R; Zhao Y; Li BL; Song M
Ai Zheng; 2007 Jan; 26(1):48-53. PubMed ID: 17222367
[TBL] [Abstract][Full Text] [Related]
31. Synergistic apoptotic effect of celecoxib and luteolin on breast cancer cells.
Jeon YW; Suh YJ
Oncol Rep; 2013 Feb; 29(2):819-25. PubMed ID: 23229294
[TBL] [Abstract][Full Text] [Related]
32. Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression.
Lamy PJ; Verjat T; Servanton AC; Paye M; Leissner P; Mougin B
Am J Clin Pathol; 2007 Sep; 128(3):404-13. PubMed ID: 17709314
[TBL] [Abstract][Full Text] [Related]
33. [Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro].
Zhu FS; Chen XM; Wang YJ; Zhang X; Feng JX
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):186-8. PubMed ID: 17649633
[TBL] [Abstract][Full Text] [Related]
34. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
[TBL] [Abstract][Full Text] [Related]
35. IL-1 beta induces urokinase-plasminogen activator expression and cell migration through PKC alpha, JNK1/2, and NF-kappaB in A549 cells.
Cheng CY; Hsieh HL; Sun CC; Lin CC; Luo SF; Yang CM
J Cell Physiol; 2009 Apr; 219(1):183-93. PubMed ID: 19097143
[TBL] [Abstract][Full Text] [Related]
36. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
37. 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathways.
Vanderlaag K; Su Y; Frankel AE; Grage H; Smith R; Khan S; Safe S
Breast Cancer Res Treat; 2008 May; 109(2):273-83. PubMed ID: 17624585
[TBL] [Abstract][Full Text] [Related]
38. TRAIL-mediated apoptosis in malignant glioma cells is augmented by celecoxib through proteasomal degradation of survivin.
Gaiser T; Becker MR; Habel A; Reuss DE; Ehemann V; Rami A; Siegelin MD
Neurosci Lett; 2008 Sep; 442(2):109-13. PubMed ID: 18634847
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.
Ohneseit PA; Krebiehl G; Dittmann K; Kehlbach R; Rodemann HP
Radiother Oncol; 2007 Feb; 82(2):229-38. PubMed ID: 17207548
[TBL] [Abstract][Full Text] [Related]
40. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
